A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs-Reference-Cited by-同舟云学术

A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs

Published:2008-12 Issue:2 Volume:194 Page:152-161
ISSN:0166-4328
Container-title:Behavioural Brain Research
language:en
Short-container-title:Behavioural Brain Research

Author:

Mihara Takuma,Iwashita Akinori,Matsuoka Nobuya

Publisher

Elsevier BV

Subject

Behavioral Neuroscience

Reference47 articles.

1. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease;Bara-Jimenez;Neurology,2003

2. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome;Bedard;Brain Cognit,1999

3. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys;Blanchet;Mov Disord,1998

4. Pharmacotherapy for Parkinson's disease;Chen;Pharmacotherapy,2007

5. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease;Close;Psychopharmacology (Berl),1990

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases;Biomolecules;2023-07-05

2. Recent Advances in the Development of Pyrimidine-based CNS Agents;Current Drug Discovery Technologies;2023-03

3. Discovery of Novel Dual Adenosine A2A and A1 Receptor Antagonists with 1H-Pyrazolo[3,4-d]pyrimidin-6-amine Core Scaffold as Anti-Parkinson’s Disease Agents;Pharmaceuticals;2022-07-25

4. Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking;PLOS Computational Biology;2021-03-19

5. Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties;MedChemComm;2018